EyeCyte is an early stage biotechnology company developing innovative treatments for the devastating eye disease, Age-Related Macular Degeneration (AMD).

Acting through a VEGF-independent pathway, EyeCyte's lead compound potently halts the new blood vessel growth that destroys vision, either when used alone or concurrently with other AMD drugs. This approach holds the potential to enhance vision for millions of sufferers.